Proteomic Analysis of Perfusate from Machine Cold Perfusion of Transplant Kidneys: Insights Into Protection from Injury.

BACKGROUND Machine cold perfusion is beneficial to the preservation of kidneys for transplantation. At the end of preservation, the perfusion solution contains many proteins. Using a proteomics approach, we searched for useful biomarkers and potential therapeutic targets in the perfusate.

Resveratrol protects against functional impairment and cardiac structural protein degradation induced by secondhand smoke exposure.

Background: Secondhand smoke (SHS) impairs cardiac function and resveratrol is cardioprotective, possibly via antioxidant and anti-inflammatory capabilities. Previously, it was shown that resveratrol protects against SHS-induced cardiac dysfunction, but the molecular mechanism is not clear.

Methods: We measured cardiac function in pigs exposed to SHS alone in a first experiment or with and without resveratrol (5 mg/kg/day) in a second experiment using echocardiography and compared this with proteomic changes.

Matrix metalloproteinase-2 is activated during ischemia/reperfusion in a model of myocardial infarction.

Background: The degradation of myosin light chain 1 (MLC1) by matrix metalloproteinase-2 (MMP-2) during ischemia/reperfusion has been implicated in the development of cardiac dysfunction. Our objective was to elucidate the role of MMP-2 and MLC1 in the development of cardiac injury and dysfunction in a model of left anterior descending (LAD) coronary artery occlusion.

Methods: Adult rats (300-350 g) were anaesthetized, and the isolated hearts were retrogradely perfused in a Langendorff apparatus.

Synergistic protection of MLC 1 against cardiac ischemia/reperfusion-induced degradation: a novel therapeutic concept for the future.

Cardiovascular diseases are a major burden to society and a leading cause of morbidity and mortality in the developed world. Despite clinical and scientific advances in understanding the molecular mechanisms and treatment of heart injury, novel therapeutic strategies are needed to prevent morbidity and mortality due to cardiac events. Growing evidence reported over the last decade has focused on the intracellular targets for proteolytic degradation by MMP-2.